ArticleBMC urology2025
Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIntravesical bacillus Calmette–Guérin (BCG) therapy is the standard adjuvant treatment for intermediate-high risk non–muscle-invasive bladder cancer (NMIBC). Transient elevations in prostate-specific antigen (PSA) following BCG instillation can prompt unnecessary prostate biopsies and increase patient anxiety. This study investigated temporal changes in total PSA levels (TPSA) and Free-to-Total PSA ratio (f/tPSA) in NMIBC patients receiving intravesical BCG therapy.
methodsWe prospectively enrolled 25 male patients with NMIBC and baseline TPSA < 4 ng/mL. Serum TPSA and free PSA were measured at three time points: prior to BCG initiation as baseline, immediately after the induction course, and three months post-treatment. Patients with prior prostate cancer, inflammatory prostate conditions, or use of medications affecting PSA were excluded. Data were analyzed using Friedman test to compare the three time points, followed by post-hoc pairwise comparisons using Wilcoxon signed-rank tests (SPSS v27).
resultsTwenty patients completed the study (mean age 64.0 ± 8.4 years), Sixteen patients (80%) exhibited a significant elevation of TPSA immediately following induction therapy. In 14 of these patients (> 80%), PSA levels spontaneously returned to near-baseline values within three months. Mean TPSA rose from 1.17 ± 1.24 ng/mL at baseline to 2.02 ± 1.48 ng/mL following intravesical BCG therapy course, the declined to 1.27 ± 1.24 ng/mL at three months post-treatment. The mean f/tPSA exhibited a steadier trend, declining from 0.30 ± 0.16 at baseline to 0.26 ± 0.12 ng/mL post-treatment, and a slight increasing to 0.28 ± 0.16 ng/mL at three months. Statistical analysis confirmed that the post-treatment elevations in TPSA and was significant (p < 0.001). No patient developed clinical or histopathological evidence of prostate cancer during follow-up.
conclusionTransient PSA elevation is a common but reversible phenomenon after intravesical BCG instillation, reflecting local inflammatory and immune responses rather than malignant transformation. In the absence of additional clinical findings, a strategy of “watchful waiting” with repeat PSA testing at three months may prevent unnecessary prostate biopsies, reduce patient anxiety, and optimize healthcare resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.